Related Blog Posts from the Wikinvest Wire

Bristol-Myers Squibb Company (BMY)   Subscribe to Bristol-Myers Squibb Company (BMY) content from the Wikinvest Wire
 » Back to Bristol-Myers S… (NYSE:BMY) Stock Page

  

5/27/15Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Announces the Ex... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today the expiration, as of 11:59 p.m., New York City time, on May 26, 2015, of its previously announced cash tender offer for up to $500 million aggregate principal amount of certain of its outstanding debt securities. Read more on this. Bristol-Myers Squibb Company (BMY), valued [...]

5/20/15Market Update (NYSE:BMY): Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Des... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has amended a previously granted Breakthrough Therapy Designation for the investigational daclatasvir and sofosbuvir combination for use in hepatitis C patients. Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $115.52B, opened at $68.41. [...]

5/13/15Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present Data at... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced new clinical research from three of its Immuno-Oncology agents will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology in Chicago from May 29-June 2. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $112.34B, started trading this morning [...]

5/6/15Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Long-Term, 7-Year Study of Nulojix® (b... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced results from a 7-year, long-term follow-up from a prospective, randomized Phase III trial in kidney transplant patients, which demonstrated a statistically significant 43% relative risk reduction of death or graft loss in patients receiving the Nulojix FDA-approved dosing regimen over those receiving a cyclosporine regimen . [...]

5/4/15Stock Update (NYSE:BMY): Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 He... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, in Las Vegas. Doug Manion, head, Specialty Development, will make a formal presentation about the company at 2:20 p.m. Read more on this. Bristol-Myers Squibb Company (BMY), valued at [...]

4/29/15Market Update (NYSE:BMY): U.S. Food and Drug Administration Accepts Supplemental Biologics Licens... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental Biologics License Application for Opdivo for the treatment of previously untreated patients with unresectable or metastatic melanoma. Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $107.15B, opened [...]

4/28/15Market Update (NYSE:BMY): Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today that it has commenced a cash tender offer for up to $400 million aggregate principal amount of specified series of its outstanding debt. Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $107.47B, began trading this morning at $64.63.   [...]

4/24/15Company Update (NYSE:BMY): EU regulators warn against combining hep C drugs with amiodarone (Jutia Group)

[Reuters - UK Focus] - European health regulators warned on Friday against using Gilead Sciences Inc's and Bristol-Myers Squibb Co's hepatitis C medicines along with amiodarone, a drug used to regulate the heartbeat of people ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $109.87B, opened at $65.82.   [...]

4/20/15Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – First Randomized Study Evaluating Opdi... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced positive results from a Phase II trial , evaluating the Opdivo +Yervoy regimen versus Yervoy alone in patients with previously untreated advanced melanoma. Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $108.64B, started the session at $65.73.   Looking [...]

4/1/15Stock Update (NYSE:BMY): Roche open to alliances in hunt for cancer drug combinations (Jutia Group)

[Reuters - UK Focus] - Roche, the world's largest cancer drugmaker, is ready to collaborate with rivals to find new combination therapies for multi-pronged treatments, its chief executive said. Severin Schwan said the company was investing very heavily in a new wave of cancer immunotherapy drugs, where finding combination therapies to attack tumours on [...]

3/27/15Market Update (NYSE:BMY): Europe pushes back verdict on Bristol immune system cancer drug (Jutia Group)

[Reuters] - European regulators have postponed a decision on whether to recommend approval of a closely watched Bristol-Myers Squibb drug that helps the immune system fight cancer, officials said on Friday. Nivolumab, which is already approved in the United States under the brand name Opdivo for melanoma and lung cancer, was on the agenda [...]

3/3/15Stock Update (NYSE:BMY): Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for ... (Jutia Group)

[Thomson Reuters ONE] - Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments; additional tiered ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $104.45B, started the session at $61.75.   Looking at [...]

3/2/15Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – U.S. Food and Drug Administration Acce... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental Biologics License Application for Yervoy for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection. Read more on this. [...]

2/26/15Market Update (NYSE:BMY): Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Sho... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced data supporting the clinical development of BMS-955176, an investigational component designed to prevent the maturation of HIV-1. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $102.14B, started the session at $61.19.   Today, shares have traded between $60.75 and $61.61 [...]

2/24/15Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Cowe... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the Cowen and Company 35th Annual Global Health Care Conference on Tuesday, March 3, 2015, in Boston. Michael Giordano, senior vice president, Head of Development, Oncology, will make a formal presentation about the company at 9:20 a.m. Read more on this. Bristol-Myers Squibb Company [...]

2/23/15Market Update (NYSE:BMY): Bristol-Myers Squibb Foundation Awards GRU Cancer Center Three-Year, $1... (Jutia Group)

[Business Wire] - The Bristol-Myers Squibb Foundation today announced a three-year, $1.74 million grant to the GRU Cancer Center for a pilot program to reduce the burden of lung cancer among underserved populations in Georgia’s Central Savannah River Area by focusing on prevention, early detection, education and helping people with suspected or diagnosed lung [...]

2/5/15Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Take Part in Le... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will take part in the Leerink Swann Global Health Care Conference on Thursday, February 12, 2015, in New York. Francis Cuss, executive vice president and chief scientific officer, will answer questions about the company at 11:10 a.m. Read more on this. Bristol-Myers Squibb Company (BMY), with a [...]

1/29/15Stock Update (NYSE:BMY): U.S. Food and Drug Administration Approves Bristol-Myers Squibb’s Evot... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $101.42B, started the session at $61.20. [...]

1/12/15Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Merck, Bristol heat up immunotherapy ... (Jutia Group)

[Reuters - UK Focus] - Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $103.14B, opened [...]

1/6/15Market Update (NYSE:BMY): Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015, in San Francisco. Giovanni Caforio, chief operating officer, will make a formal presentation about the company at 9 a.m. Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $98.30B, [...]

1/5/15Company Update (NYSE:BMY): Bristol-Myers Squibb and California Institute for Biomedical Research ... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and the California Institute for Biomedical Research announced today they have entered into a worldwide research collaboration to d Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $97.17B, started trading this morning at $59.36.   Today, shares have traded between $58.04 [...]

12/17/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Announce Resul... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will announce results for the fourth quarter and full year of 2014 on Tuesday, January 27, 2015. During a conference call at 9 a.m. EST on J Read more on this. Bristol-Myers Squibb Company (BMY), valued at $96.23B, started trading this morning at $57.87.   [...]

12/3/14Market Update (NYSE:BMY): Bristol-Myers Squibb Foundation Awards Nine Grants Totaling More than $... (Jutia Group)

[Business Wire] - NEW YORK--(BUSINESSWIRE)-- The Bristol-Myers Squibb Foundation today announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $98.07B, started trading this morning at $59.26.   [...]

12/1/14Market Update (NYSE:BMY): Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 ... (Jutia Group)

[Business Wire] - The Bristol-Myers Squibb Foundation today marked World AIDS Day by announcing 12 new grants totaling $1.47 million that focus on strengthening community-based services in sub-Sahar Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $98.58B, started trading this morning at $59.21.   Looking [...]

11/24/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and Five Prime Th... (Jutia Group)

[GlobeNewswire] - NEW YORK and SOUTH SAN FRANCISCO, Calif. -- Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. today announced that they have entered into an exclusive clinical collaboration agreement to evaluate ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $97.75B, started the session at $58.92.   [...]

11/17/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Portola, Bristol-Myers Squibb and Pfiz... (Jutia Group)

[GlobeNewswire] - -- Andexanet Alfa Rapidly Reversed the Anticoagulant Effect of the Factor Xa Inhibitor Eliquis (apixaban) Among All Study Participants -- Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $96.39B, finished yesterday at $57.95.   Looking at today's market, BMY one day range is $57.73 to [...]

11/12/14Market Update (NYSE:BMY): Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstra... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today that 16 abstracts for Orencia were accepted for presentation at the 2014 annual meeting of the American College of Rheumatology taking place from November 14-19, 2014 in Boston, MA. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $97.34B, started the session at $58.68. [...]

11/7/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Multiple Bristol-Myers Squibb Oncology ... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced that study results on investigational agents Opdivo , a PD-1 immune checkpoint inhibitor, elotuzumab, an antibody targeted against Signaling Lymphocyte Activation Molecule , ulocuplumab, an anti-CXCR4 antibody, and Sprycel , will be featured in oral presentations at the 56th annual meeting of the American Society for [...]

11/5/14Company Update (NYSE:LLY): Lilly’s CYRAMZA® (ramucirumab) in Combination with Paclitaxel Grant... (Jutia Group)

[PR Newswire] - INDIANAPOLIS, Nov. 5, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA ® (ramucirumab) in combination with paclitaxel ... Read more on this. Eli Lilly and Company (LLY), currently valued at $71.65B, started the session at $67.47. [...]

11/4/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Cre... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the Credit Suisse Annual Health Care Conference on Tuesday, November 11, 2014 in Phoenix. Charles Bancroft, executive vice president and chief financial officer, will make a formal presentation about the company at 8:30 a.m. Read more on this. Bristol-Myers Squibb Company (BMY), currently valued [...]

11/3/14Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Signs Exclusive ... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Galecto Biotech AB today announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase [...]

10/30/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Phase 2 Objective Response Rate and Su... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo , an investigational PD-1 immune checkpoint inhibitor, administered as a single agent in patients with advanced squamous cell non-small cell lung cancer who have progressed after at least two prior systemic treatments with 65% [...]

10/24/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Reports Third Qua... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today reported strong financial results for the third quarter of 2014, adjusted 2014 GAAP guidance and confirmed 2014 non-GAAP guidance. The Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $89.34B, began trading this morning at $52.65.   A quick look at [...]

10/13/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb, Pharmacyclics and... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company , Pharmacyclics, Inc. , and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO® in combination with IMBRUVICA® , an oral Bruton's tyrosine kinase [...]

9/26/14Stock Update (NYSE:BMY): Bristol immunotherapy gets 6-month U.S. FDA review for melanoma (Jutia Group)

[Reuters - UK Focus] - The U.S. Food and Drug Administration has granted a six-month, priority review to Bristol-Myers Squibb Co's application for immuno-oncology drug Opdivo as a treatment for previously treated melanoma, the ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $84.72B, opened at $51.78. [...]

9/11/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Bank... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the Bank of America Merrill Lynch Global Health Care Conference on Thursday, September 18, 2014, in London. John Elicker, senior vice president, Public Affairs and Investor Relations, will make a formal presentation about the company at 9:45 a.m. Read more on this. Bristol-Myers Squibb [...]

9/2/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Take Part in Mo... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will take part in the Morgan Stanley 2014 Global Health Care Conference on Monday, September 8, 2014, in New York. Giovanni Caforio, chief operating officer, will answer questions about the company at 2 p.m. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $83.86B, started the [...]

8/27/14Market Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb’s Daklinza (daclata... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced that the European Commission has approved Daklinza , a potent, pan-genotypic NS5A replication complex inhibitor , for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults. Read more on this. [...]

8/21/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – U.S. FDA Approves Eliquis (apixaban) fo... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced the U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Read more on this. Bristol-Myers [...]

8/20/14Stock Update (NYSE:BMY): Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixab... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. announced today that they will present 14 abstracts at the ESC Congress 2014, organized by the European Society of Cardiology, to be held August 30 to September 4 in Barcelona, Spain. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $83.04B, opened at [...]

8/7/14Bristol-Myers Squibb Company (NYSE:BMY) | Leica Biosystems and Bristol-Myers Squibb Enter Into a ... (Jutia Group)

[PR Newswire] - Leica Biosystems announces a collaboration with Bristol-Myers Squibb to develop companion diagnostic tests in support of targeted therapeutics Leica Biosystems will develop fully automated tissue-based companion diagnostic tests to run on the BOND™ automated advanced staining systems Leica Biosystems, today announced an agreement with Bristol-Myers Squibb Company (BMY) to collaborate on [...]

8/4/14Bristol-Myers Squibb Company (NYSE:BMY) – Allied Minds and Bristol-Myers Squibb Form New Enterp... (Jutia Group)

[at noodls] - Allied-Bristol Life Sciences LLC to identify and speed development of promising science and technologies Unique collaboration focused on transforming early-stage academic innovation to therapeutic candidates ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $82.71B, opened this morning at $49.82.   A quick look at [...]

7/29/14Company Update (NYSE:BMY): European Commission Approves Eliquis (apixaban) for the Treatment of D... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $83.57B, started the session at [...]

7/24/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Reports Second Quarter 2014 Fina... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today reported financial results for the second quarter of 2014, which was highlighted by strong global sales for the company’s key brands; the achievement of important regulatory milestones for key brands in Japan, Europe and the U.S.; a new strategic immuno-oncology collaboration agreement with Ono Pharmaceutical Co., Ltd.; [...]

7/1/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Announce Resul... (Jutia Group)

[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter on Thursday, July 24, 2014. During a conference call at 10:30 a.m. EDT on July 24, company ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $79.63B, opened at $48.48.   [...]

6/27/14Bristol-Myers Squibb Company (NYSE:BMY) – Eliquis® (apixaban) Receives CHMP Positive Opinion f... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that Eliquis be granted marketing authorization for the treatment of DVT and PE , and the prevention of recurrent DVT and PE, in [...]

6/17/14Stock Update (NYSE:BMY): Bristol-Myers Squibb Announces Dividend (Jutia Group)

[Business Wire] - The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of thirty-six cents per share on the $.10 par value Common Stock of the corporation. Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $78.65B, started the session at $47.23.   Today’s [...]

6/3/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and Syngene Inter... (Jutia Group)

[Business Wire] - PRINCETON, N.J. & BANGALORE, India--(BUSINESSWIRE)-- Bristol-Myers Squibb (NYSE:BMY - News) and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India. Since 2007, Bristol-Myers Squibb has been working with Syngene and its corporate parent, Biocon Ltd., to develop integrated capabilities [...]

5/19/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and AbbVie Receive U.S. FDA Brea... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and AbbVie today announced that the U.S. Food and Drug Administration has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies. Read more [...]

5/16/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Hold Investor T... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will host a teleconference on Monday, June 2, 2014, at 8 a.m. EDT to review data presented at the Annual Meeting of the American Society of Clinical Oncology in Chicago. Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $80.85B, started trading [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki